Opus Genetics Inc (IRD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -73,633 | -65,535 | -49,591 | -33,068 | -15,614 |
| Depreciation Amortization | 27 | 13 | 53 | 40 | 27 |
| Accounts receivable | 954 | 264 | 1,568 | 647 | 164 |
| Accounts payable and accrued liabilities | -1,412 | 1,155 | 7 | -797 | -1,703 |
| Other Working Capital | 893 | -102 | -2,154 | -2,227 | -3,102 |
| Other Operating Activity | 48,494 | 51,478 | 14,864 | 9,985 | 965 |
| Operating Cash Flow | $-24,677 | $-12,727 | $-35,253 | $-25,420 | $-19,263 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 35,000 | N/A | 1,000 | 1,000 | 1,000 |
| Common Stock Issued | 10,135 | 27,781 | 49,175 | 27,153 | 21,914 |
| Common Stock Repurchased | -33 | -33 | -152 | -36 | -36 |
| Other Financing Activity | 23,396 | -153 | 0 | -2,203 | -1,507 |
| Financing Cash Flow | $68,498 | $27,595 | $50,023 | $25,914 | $21,371 |
| Beginning Cash Position | 45,091 | 45,091 | 30,321 | 30,321 | 30,321 |
| End Cash Position | 88,912 | 59,959 | 45,091 | 30,815 | 32,429 |
| Net Cash Flow | $43,821 | $14,868 | $14,770 | $494 | $2,108 |
| Free Cash Flow | |||||
| Operating Cash Flow | -24,677 | -12,727 | -35,253 | -25,420 | -19,263 |
| Free Cash Flow | -24,677 | -12,727 | -35,253 | -25,420 | -19,263 |